From genes to proteins in Mendelian Parkinson's disease: An overview

Anatomical Record

Volumn 292, Issue 12, 2009, Pages 1893-1901

  Pirkevi, Caroline ^a   Lesage, Suzanne ^b,c   Brice, Alexis ^b,c,d   Başak, A Nazli ^a  

^a BOGAZICI UNIVERSITY   (Turkey)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

ATP13A2; DJ1; Familial Parkinson's disease; Genetics; LRRK2; Parkin; PINK1; SNCA

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE TYPE 13A2; ALPHA SYNUCLEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PARKIN; UBIQUITIN C; UBIQUITIN C TERMINAL HYDROLASE L1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DOMINANT INHERITANCE; DRUG RESPONSE; GENE MUTATION; GENE REARRANGEMENT; HETEROZYGOSITY; HUMAN; KUFOR RAKEB SYNDROME; LEWY BODY; LINKAGE ANALYSIS; MISSENSE MUTATION; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; RECESSIVE INHERITANCE; UBIQUITINATION;

ALPHA-SYNUCLEIN; ANIMALS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE TISSUE PROTEINS; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 73849135183     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.20968     Document Type: Conference Paper

References (110)

1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. 2000. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252.
2. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. 2004. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 351:1972-1977.
3. Al Din N, Wriekat A, Mubaidin A, Dasouki M, Hiari M. 1994. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 89:347-352.
4. Bonifati V. 2007. Genetics of Parkinsonism. Parkinsonism Relat Disord 13:S233-S241.
5. Bonifati V, Breedveld GJ, Squitieri F, Vanacore N, Brustenghi P, Harhangi BS, Montagna P, Cannella M, Fabbrini G, Rizzu P, van Duijn CM, Oostra BA, Meco G, Heutink P. 2002. Localization of autosomal recessive early-onset Parkinsonism to chromosome 1p36 (PARK7) in an independent data set. Ann Neurol 51:253-256.
6. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. 2003. Mutations in the DJ1 gene associated with autosomal recessive early-onset Parkinsonism. Science 299:256-259.
7. Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P, De Gaetano A, Horstink MW, Maat-Kievit JA, Sampaio C, Antonini A, Stocchi F, Montagna P, Toni V, Guidi M, Dalla Libera A, Tinazzi M, De Pandis F, Fabbrini G, Goldwurm S, de Klein A, Barbosa E, Lopiano L, Martignoni E, Lamberti P, Vanacore N, Meco G, Oostra BA. 2005. Early-onset Parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65:87-95.
8. Bras J, Simon-Sanchez J, Federoff M, Morgadinho A, Januario C, Ribeiro M, Cunha L, Oliveira C, Singleton AB. 2009. Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum Mol Genet 18:341-346.
9. Brice A. 2005. Genetics of Parkinson's disease: LRRK2 on the rise. Brain 128:2760-2762.
10. Chen L, Feany MB. 2005. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a drosophila model of Parkinson disease. Nat Neurosci 8:657-663.
11. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. 2006. Drosophila PINK1 is required for mitochondrial function and interacts genetically with Parkin. Nature 441:1162-1166.
12. Conway KA, Lee SJ, Rochet JC, Ding TT, Harper JD, Williamson RE, Lansbury PT Jr. 2000. Accelerated oligomerization by Parkinson's disease linked α-synuclein mutants. Ann NY Acad Sci 920:42-45.
13. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. 2001. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α- synuclein adduct. Science 294:1346-1349.
14. Corti O, Hampe C, Koutnikova H, Darios F, Jacquier S, Prigent A, Robinson JC, Pradier L, Ruberg M, Mirande M, Hirsch E, Rooney T, Fournier A, Brice A. 2003. The p38 subunit of the aminoacyltRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 12:1427-1437.
15. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. 2004. Impaired degradation of mutant α-synuclein by chaperonemediated autophagy. Science 305:1292-1295.
16. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, Abbas N, Gu WJ, Hirsch EC, Rooney T, Ruberg M, Brice A. 2003. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12:517-526.
17. Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, Fabbrini G, Marconi R, Fincati E, Abbruzzese G, Marini P, Squitieri F, Horstink MW, Montagna P, Libera AD, Stocchi F, Goldwurm S, Ferreira JJ, Meco G, Martignoni E, Lopiano L, Jardim LB, Oostra BA, Barbosa ER, Bonifati V. 2007. ATP13A2 missense mutations in juvenile Parkinsonism and young onset Parkinson disease. Neurology 68:1557-1562.
18. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V. 2006. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14:322-331.
19. Fahn S. 2003. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 991:1-14.
20. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW. 2004. Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55:174-179.
21. Farrer MJ. 2006. Genetics of Parkinson's disease: paradigm shifts and future prospects. Nat Rev Genet 7:306-318.
22. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, Farrer MJ. 2007. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68:916-922.
23. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S. 2009. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41:308-315.
24. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. 2006. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15:223-232.
25. Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E. 2006. Glucocerebrosidase mutations are an important risk factors for Lewy body disorders. Neurology 67:908-910.
26. Goldberg MS and Lansbury PT, Jr. 2000. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2:E115-E119.
27. Greene JC, Whitworth AJ, Andrews LA, Parker TJ, Parker TJ, Pallanck LJ. 2005. Genetic and genomic studies of drosophila Parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet 14:799-811.
28. Hampe C, Ardila-Osorio H, Fournier M, Brice A, Corti O. 2006. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet 15:2059-2075.
29. Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, Yoshino H, Asahina M, Kobayashi S, Hassin-Baer S, Lu CS, Ng AR, Rosales RL, Shimizu N, Toda T, Mizuno Y, Hattori N. 2004. Novel PINK1 mutations in early-onset Parkinsonism. Ann Neurol 56:424-427.
30. Healy DG, Abou-Sleiman PM, Gibson JM, Ross OA, Jain S, Gandhi S, Gosal D, Muqit MM, Wood NW, Lynch T. 2004. PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology 63:1486-1488.
31. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW. 2008. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7:583-590.
32. Hedrich K, Eskelson C, Wilmot B, Marder K, Harris J, Garrels J, Meija-Santana H, Vieregge P, Jacobs H, Bressman SB, Lang AE, Kann M, Abbruzzese G, Martinelli P, Schwinger E, Ozelius LJ, Pramstaller PP, Klein C, Kramer P. 2004. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 19:1146-1157.
33. Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ. 2008. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 7:591-594.
34. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. 2007. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16:1319-1326.
35. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A. 2004. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364:1169-1171.
36. Ibanez P, Lesage S, Janin S, Lohmann E, Durif F, Destee A, Bonnet AM, Brefel-Courbon C, Heath S, Zelenika D, Agid Y, Durr A, Brice A. 2009. Alpha-synuclein gene rearrangements in dominantly inherited Parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 66:102-108.
37. Ibanez P, Lesage S, Lohmann E, Thobois S, De Michele G, Borg M, Agid Y, Durr A, Brice A. 2006. Mutational analysis of the PINK1 gene in early-onset Parkisonism in Europe and North-Africa. Brain 129:686-694.
38. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. 2005. Identification of a novel LRRK2 mutation linked to autosomal dominant Parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672-680.
39. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bjorklund A. 2002. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J Neurosci: 22:2780-2791.
40. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Moshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392:605-608.
41. Klein C, Djarmati A, Hedrich K, Schafer N, Scaglione C, Marchese R, Kock N, Schule B, Hiller A, Lohnau T, Winkler S, Wiegers K, Hering R, Bauer P, Riess O, Abbruzzese G, Martinelli P, Pramstaller PP. 2005. PINK1, Parkin and DJ1 mutations in Italian patients with early-onset Parkinsonism. Eur J Hum Genet 13:1086-1093.
42. Klein C and Lohmann-Hedrich K. 2007. Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol 20:453-464.
43. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. 2007. Deciphering the role of heterozygous mutations in genes associated with Parkinsonism. Lancet Neurol 6:652-662.
44. Klinefelter GR, Laskey JW, Ferrell J, Suarez JD, Roberts NL. 1997. Discriminant analysis indicates a single sperm protein (SP22) is predictive of fertility following exposure to epididymal toxicants. J Androl 18:139-150.
45. Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL, Song H, Park BJ, Kim MJ, Kim S, Dawson VL, Dawson TM. 2005. Accumulation of the authentic Parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25:7968-7978.
46. Kostka M, Hogen T, Danzer KM, Levin J, Habeck M, Wirth A, Wagner R, Glabe CG, Finger S, Heinzelmann U, Garidel P, Duan W, Ross CA, Kretzschmar H, Giese A. 2008. Single particle characterization of iron-induced pore-forming α-synuclein oligomers. J Biol Chem 283:10992-11003.
47. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18:106-108.
48. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT, Jr. 2002. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089-1102.
49. Lautier C, Goldwurm S, Durr A, Giovannone B, Tsiaras WG, Pezzoli G, Brice A, Smith RJ. 2008. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 82:822-833.
50. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. 2004. Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24:1888-1896.
51. Lesage S and Brice A. 2009. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18:R48-R59.
52. Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F, Damier P, Thobois S, Ouvrard-Hernandez AM, Rivaud-Pechoux S, Brefel-Courbon C, Destee A, Tranchant C, Romana M, Leclere L, Durr A, Brice A. Molecular analyses of the LRRK2 gene in European and North-African autosomal dominant Parkinson's disease. J Med Genet, in press.
53. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A. 2006. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354:422-423.
54. Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Durr A, Brice A. 2005. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77:330-332.
55. Li Y, Tomiyama H, Sato K, Hatano Y, Yoshino H, Atsumi M, Kitaguchi M, Sasaki S, Kawaguchi S, Miyajima H, Toda T, Mizuno Y, Hattori N. 2005. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset Parkinsonism. Neurology 64: 1955-1957.
56. Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y, Tanaka Y, Smith W, S Engelender, Ross CA, Dawson VL, Dawson TM. 2005. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 25:2002-2009.
57. Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT Jr. 2009. Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci USA 106:4635-4640.
58. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, Aebischer P. 2004. Lentiviral vector delivery of Parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci USA 101:17510-17515.
59. Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussolle E, Horstink MW, Vidailhet M, Verpillat P, Gasser T, Nicholl D, Teive H, Raskin S, Rascol O, Destee A, Ruberg M, Gasparini F, Meco G, Agid Y, Durr A, Brice A. 2003. How much phenotypic variation can be attributed to Parkin genotype? Ann Neurol 54:176-185.
60. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, Agid Y, Brice A. 2000. Association between early-onset Parkinson's disease and mutations in the Parkin gene. N Engl J Med 342:1560-1567.
61. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. 2004. Glucocerebrosidase mutations in subjects with Parkinsonism. Mol Genet Metab 81:70-73.
62. Macedo MG, Anar B, Bronner IF, Cannella M, Squitieri F, Bonifati V, Hoogeveen A, Heutink P, Rizzu P. 2003. The DJ1 L166P mutant protein associated with early-onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum Mol Genet 12:2807-2816.
63. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. 2006. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29:286-293.
64. Mc Naught K St P and Olanow CW. 2006. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neuro Biol Aging 27:530-545.
65. Meeus B, Nuytemans K, Crosiers D, Engelborghs S, Pals P, Pickut B, Peeters K, Mattheijssens M, Corsmit E, Cras P, De Deyn PP, Theuns J, Van Broeckhoven C. GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. Neurobiol Aging, in press.
66. Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, Mc Lendon C, Carter DM, Zhu PP, Stadler J, Chandran J, Klinefelter GR, Blackstone C, Cookson MR. 2003. L166P mutant DJ1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-protasome system. J Biol Chem 278:36588-36595.
67. Mitsumoto A, Nakagawa Y. 2001. DJ1 is an indicator for endogenous reactive active species elicited by endotoxin. Free Radic Res 35:885-893.
68. Moore DJ, Zhang L, Dawson TM, Dawson VL. 2003. A missense mutation (L166P) in DJ1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem 87:1558-1567.
69. Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, Suda K, Mizuno Y. 1998. Pathologic and biochemical studies of juvenile Parkinsonism linked to chromosome 6q. Neurology 51:890-892.
70. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H. 1997. DJ1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231:509-513.
71. Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T. 2007. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69:1737-1744.
72. Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T. 2009. Variation in GIGYF2 is not associated with Parkinson disease. Neurology 72:1886-1892.
73. Nuytemans K, Rademakers R, Theuns J, Pals P, Engelborghs S, Pickut B, de Pooter T, Peeters K, Mattheijssens M, Van den Broeck M, Cras P, De Deyn PP, van Broeckhoven C. 2008. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur J Hum Genet 16:471-479.
74. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. 2006. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354:424-425.
75. Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, Schneider SA. 2008. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 65:19-23.
76. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600.
77. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. 2006. Mitochondrial dysfunction in drosophila PINK1 mutants is complemented by Parkin. Nature 441:1157-1161.
78. Pirkevi C, Lesage S, Condroyer C, Tomiyama H, Hattori N, Ertan S, Brice A, Başak AN. 2009. A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype. Neurogenetics 10:271-273.
79. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
80. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ. 2008. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105:1638-1643.
81. Pridgeon JW, Olzmann JA, Chin LS, Li L. 2007. PINK1 protects against oxidative stress by phosphoylating mitochondrial chaperone TRAP1. PloS Biol 5:1494-1503.
82. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C. 2006. Hereditary Parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38:1184-1191.
83. Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, Sato C, Morgan A, Werner J, Nussbaum R, Petit A, Okun MS, McInerney A, Mandel R, Groen JL, Fernandez HH, Postuma R, Foote KD, Salehi-Rad S, Liang Y, Reimsnider S, Tandon A, Hardy J, St George-Hyslop P, Singleton AB. 2004. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 61:1898-1904.
84. Ross OA, Spanaki C, Griffith A, Lin CH, Kachergus J, Haugarvoll K, Latsoudis H, Plaitakis A, Ferreira JJ, Sampaio C, Bonifati V, Wu RM, Zabetian CP, Farrer MJ. 2009. Haplotype analysis of LRRK2 R1441H carriers with Parkinsonism. Parkinsonism Relat Dis 15:466-467.
85. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. 2004. DJ1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PloS Biol 2:e362.
86. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. 2000. Familial Parkinson disease gene product, Parkin, is a ubiquitin-protein ligase. Nat Genet 25:302-305.
87. Shojaee S, Sina F, Banihosseini SS, Kazemi MH, Kalhor R, Shahidi GA, Fakhrai-Rad H, Ronaghi M, Elahi E. 2008. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500K SNP arrays. Am J Hum Genet 82:1375-1384.
88. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302:841.
89. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. 2006. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231-1233.
90. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-840.
91. Sutherland GT, Siebert GA, Newman JR, Silburn PA, Boyle RS, O'Sullivan JD, Mellick GD. 2009. Haplotype analysis of the PARK 11 gene, GIGYF2, in sporadic Parkinson's disease. Mov Disord 24:449-452.
92. Takahashi R, Imai Y, Hattori N, Mizuno Y. 2003. Parkin and endoplasmic reticulum stress. Ann NY Acad Sci 991:101-106.
93. Tan EK and Jankovic J. 2006. Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol 63:1232-1237.
94. Thomas B and Beal MF. 2007. Parkinson's disease. Hum Mol Genet 16:R183-R194.
95. Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, Djaldetti R, Melamed E, Amouri R, Gouider-Khouja N, Hentati F, Hatano Y, Wang M, Imamichi Y, Mizoguchi K, Miyajima H, Obata F, Toda T, Farrer MJ, Mizuno Y, Hattori N. 2006. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Dis 21:1102-1108.
96. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. 2004a. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160.
97. Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW. 2001. Localization of a novel locus for autosomal recessive early-onset Parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 68:895-900.
98. Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, Bentivoglio AR. 2004b. PINK1 mutations are associated with sporadic early-onset Parkinsonism. Ann Neurol 56:336-341.
99. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, Dawson VL, Dawson TM. 2004. Loss of locus coeruleus neurons and reduced startle in Parkin null mice. Proc Natl Acad Sci USA 101:10744-10749.
100. Wagenfeld A, Gromoll J, Cooper TG. 1998. Molecular cloning and expression of rat contraception associated protein 1 (CAP1), a protein putatively involved in fertilization. Biochem Biophys Res Commun 251:545-549.
101. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102:16842-16847.
102. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AJ, Zimprich A, Muller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW. 2004. Autosomal dominant Parkinsonism associated with variable synuclein and tau pathology. Neurology 62:1619-1622.
103. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H, Lu B. 2006. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of drosophila PINK1 is rescued by Parkin. Proc Natl Acad Sci USA 103:10793-10798.
104. Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H, Mizusawa H. 2003. Down-regulation of DJ1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 312:1342-1348.
105. Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, Leis BC, Bird TD, Nutt JG, Higgins DS, Roberts JW, Kay DM, Edwards KL, Samii A, Payami H. 2006a. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79:752-758.
106. Zabetian CP, Morino H, Ujike H, Yamamoto M, Oda M, Maruyama H, Izumi Y, Kaji R, Griffith A, Leis BC, Roberts JW, Yearout D, Samii A, Kawakami H. 2006b. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 67:697-699.
107. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173.
108. Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI, Torp R, Torgner IA, Ottersen OP, Dawson TM, Dawson VL. 2005. Mitochondrial localization of the Parkinson's disease related protein DJ1: implications for pathogenesis. Hum Mol Genet 14:2063-2073.
109. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. 2004. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 44:601-607.
110. Zimprich A, Schulte C, Reinthaler E, Haubenberger D, Balzar J, Lichtner P, El Tawil S, Edris S, Foki T, Pirker W, Katzenschlager R, Daniel G, Brucke T, Auff E, Gasser T. PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. Parkinsonism Relat Disord, in press.